Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd pointsOnset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study
Loggers E, Chugh R, Federman N, Hartner L, Riedel R, Cho S, Hyslop D, Lim A, Oton A, Oktay K. Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. Cancer 2024, 130: 2812-2821. PMID: 38703010, DOI: 10.1002/cncr.35324.Peer-Reviewed Original ResearchFemales of reproductive potentialFollicle-stimulating hormoneReturn of menstruationOvarian toxicityDesmoid tumorsFollow-upContinuous 28-day cyclesLost to follow-upPhase 3 studyProgressive desmoid tumorsPost hoc analysisSafety populationNirogacestatStopping treatmentHormone valuesSafety signalsHoc analysisPatientsPerimenopausal symptomsMenstruationGamma-secretase inhibitorsPlaceboRandom femalesTumorEvent follow-up
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply